New drug candidate UP-818-CC passes first safety check in healthy people
NCT ID NCT07355621
First seen Jan 25, 2026 · Last updated May 20, 2026 · Updated 16 times
Summary
This early-stage study tested the safety and tolerability of a new drug called UP-818-CC in 73 healthy Chinese volunteers. Participants received either a single dose or multiple daily doses of the drug or a placebo by IV infusion. The goal was to check for side effects and how the drug moves through the body, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.